[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100588822":3},{"organization":4,"outcomesModule":7,"designInfo":63,"detailedDescription":69,"studyPopulation":62,"armGroups":70,"interventions":82,"overallOfficials":90,"centralContacts":94,"locations":62,"responsibleParty":102,"collaborators":104,"id":108,"slug":62,"hasResults":109,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":62,"eligibilityCriteria":113,"healthyVolunteers":109,"sex":114,"minAge":115,"maxAge":116,"enrollmentInfo":117,"targetDuration":62,"studyType":120,"phases":121,"briefSummary":123,"conditions":124,"keywords":126,"overallStatus":128,"whyStopped":62,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":62},{"fullName":5,"class":6},"The First Affiliated Hospital of Dalian Medical University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":62},[9],{"measure":10,"description":11,"timeFrame":12},"Changes of mean Hb levels from baseline in the standard medication regimen group and the optimized medication regimen group at week 24 of the treatment period.","Baseline Hb was defined as the assessments of Hb during 3days prior to first dose of the study treatment. Mean Hb levels at week 24 of the treatment period (Hb at week 24) was defined as the mean of Hb at day 168±5 of the treatment period. Changes of mean Hb levels from baseline in the standard medication regimen group and the optimized medication regimen group at week 24 of the treatment period was calculated by subtracting the baseline Hb from Hb at week 24.","the 24th week of treatment.",[14,18,21,24,27,30,34,37,41,45,49,53,56,59],{"measure":15,"description":16,"timeFrame":17},"Median time for two groups of Hb values to reach the target for the first time","Median time for two groups of Hb values to reach the target for the first time.","during the 48 weeks of treatment.",{"measure":19,"description":20,"timeFrame":17},"Proportion of subjects with Hb levels meeting the standard in two groups at each follow-up point","Proportion of subjects with Hb levels meeting the standard in two groups at each follow-up point.",{"measure":22,"description":23,"timeFrame":17},"Change of Hb from baseline at each follow-up point","Change of Hb from baseline at each follow-up point.",{"measure":25,"description":26,"timeFrame":17},"Change of red blood cell count from baseline at each follow-up point","Change of red blood cell count from baseline at each follow-up point.",{"measure":28,"description":29,"timeFrame":17},"Change of hematocrit from baseline at each follow-up point","Change of hematocrit from baseline at each follow-up point.",{"measure":31,"description":32,"timeFrame":33},"the fluctuation of Hb values between the two groups after 24 weeks (Hb variability)","It was defined as the coefficient of variation of Hb values after 24 weeks, which was calculated by dividing the SD (standard deviation) by the mean of Hb after the 24 weeks of treatment.","after the 24 weeks of treatment.",{"measure":35,"description":36,"timeFrame":17},"The types and average doses of anti-anemia drugs of the subjects reaching the Hb target at each follow-up time point","The types and average doses of anti-anemia drugs of the subjects reaching the Hb target at each follow-up time point.",{"measure":38,"description":39,"timeFrame":40},"Cumulative number of dose adjustments for both groups of subjects in weeks 24 and 48","Cumulative number of dose adjustments for both groups of subjects in weeks 24 and 48.","the 24th and 48th week of treatment.",{"measure":42,"description":43,"timeFrame":44},"Therapeutic response of populations with different baseline characteristics to pegmolesatide","Changes of mean Hb levels of populations with different baseline characteristics from baseline at week 24 of the treatment period.","at the week 24 of treatment.",{"measure":46,"description":47,"timeFrame":48},"Patient reported outcomes (PROs) at baseline and at week 24 in both groups","Health Survey Scale at baseline and at week 24 in both groups.","baseline and the 24th week of treatment",{"measure":50,"description":51,"timeFrame":52},"All-cause death","Number of all-cause death events during the 24\u002F48 weeks of treatment.","during the 24\u002F48 weeks of treatment.",{"measure":54,"description":55,"timeFrame":52},"Cardiovascular death","Number of cardiovascular death events during the 24\u002F48 weeks of treatment.",{"measure":57,"description":58,"timeFrame":52},"Cerebral infarction and myocardial infarction","Number of Cerebral infarction and myocardial infarction events during the 24\u002F48 weeks of treatment.",{"measure":60,"description":61,"timeFrame":52},"Receive regular renal replacement therapy","Number of subjects receive regular renal replacement therapy during the 24\u002F48 weeks of treatment.",null,{"allocation":64,"interventionModel":65,"interventionModelDescription":62,"primaryPurpose":66,"observationalModel":62,"timePerspective":62,"maskingInfo":67},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":68,"maskingDescription":62,"whoMasked":62},"NONE","This was a multicenter, randomized, open label, non inferiority clinical study. It consisted of a 24-week treatment period (0-24 weeks) and a 24-week extension period (25-48 weeks). About 160 patients were randomized in a 1:1 ratio to Pegmolesatide optimize medication regimen group and Pegmolesatide standard medication regimen group. Patients in the investigational group received 2.0 mg (in patients weighing ≤60 kg) or 3.2 mg (in patients weighing \\>60 kg) as the initial dose, the initial dose of the control group was 0.04mg\u002Fkg, then were adjusted for every 4 weeks based on Hb levels and its changes. The primary endpoint was the change in Hb levels from baseline in week 24.",[71,77],{"label":72,"type":73,"description":74,"interventionNames":75},"Pegmolesatide optimize medication regimen group","EXPERIMENTAL","initial phase：Body weight ≤60kg, initial dose 2.0mg; Body weight \\> 60kg, initial dose 3.2mg, once every 4 weeks by subcutaneous injection.\n\nAdjustment phase：based on Hb levels and its changes every 4 weeks, once a month by subcutaneous injection.",[76],"Drug: Pegmolesatide",{"label":78,"type":79,"description":80,"interventionNames":81},"Pegmolesatide standard medication regimen group","ACTIVE_COMPARATOR","initial phase：0.04mg\u002Fkg body weight, once every 4 weeks by subcutaneous injection.\n\nAdjustment phase：based on Hb levels and its changes every 4 weeks, once a month by subcutaneous injection.",[76],[83],{"type":84,"name":85,"description":86,"armGroupLabels":87,"otherNames":88},"DRUG","Pegmolesatide","Pegmolesatide Injection: Specification 1mL: 4.0mg (National Medical Products Administration Approval No. H20230020), administered once every 4 weeks",[72,78],[89],"EPO-018B",[91],{"name":92,"affiliation":5,"role":93},"Hongli Lin, M.D.","PRINCIPAL_INVESTIGATOR",[95,99],{"name":92,"role":96,"phone":97,"phoneExt":62,"email":98},"CONTACT","13332268576","linhongli@vip.163.com",{"name":100,"role":96,"phone":101,"phoneExt":62,"email":62},"Jilin Chen, M.D.","18098875658",{"type":103,"investigatorFullName":62,"investigatorTitle":62,"investigatorAffiliation":62,"oldNameTitle":62,"oldOrganization":62},"SPONSOR",[105],{"name":106,"class":107},"Jiangsu Hansoh Pharmaceutical Co., Ltd.","INDUSTRY","100588822",false,"NCT06946394","Two Different Regiments of Pegmolesatide for Anemia in Patients With Chronic Kidney Disease Not Receiving Dialysis","Application of Pegmolesatide in Renal Anemia: the Effectiveness and Safety of Switching to Two Different Regimens of Pegmolesatide in Patients With Non Dialysis CKD Treated With rhuEPO or HIF-PHI","Inclusion Criteria:\n\n1. Age ≥ 18 years old and ≤ 80 years old, gender not limited;\n2. Weight ≥ 45kg; Body Mass Index (BMI) ≥ 18.5kg\u002Fm\\^2;\n3. Diagnosed with CKD ≥ 6 months and estimated glomerular filtration rate (eGFR) ≥ 15mL\u002Fmin\u002F1.73m\\^2 before enrollment, and\\\u003C60 mL\u002Fmin\u002F1.73m\\^2 (estimated GFR using CKD-EPI formula), with no expected renal replacement therapy plan during the study period;\n4. rHuEPO or HIF-PHI should be used for ≥ 4 weeks and ≤ 12 weeks;\n5. During the 28days and 3days before randomization, with Hb ≥ 70g\u002FL and \\\u003C 110g\u002FL;\n6. Understand the research procedure and voluntarily sign an informed consent form (ICF) in writing.\n\nExclusion Criteria:\n\n1. Known to have hematological disorders or other diseases that cause anemia other than chronic kidney disease (CKD), such as primary pure red cell aplasia (PRCA), homozygous sickle cell disease, thalassemia\u002FCooley's anemia, multiple myeloma, hemolytic anemia, and myelodysplastic syndrome, or malignant tumors;\n2. Known to be allergic to iron agents or polyethylene glycol;\n3. Received red blood cell or whole blood transfusion therapy within the three months prior to randomization;\n4. Have received oral or intravenous immunosuppressive or glucocorticoid therapy within the 12 weeks prior to randomization;\n5. Individuals with poor blood pressure control;\n6. C-reactive protein ≥ 30mg\u002FL within the first 3 days of randomization;\n7. Pregnant and lactating women, women of childbearing age who have a positive urine β - HCG test result before the trial, or those who have a pregnancy plan during the study period;\n8. Assessment of cardiac function level III or IV within the first 3 days of randomization;\n9. Within the first 3 days of randomization, the liver function was assessed as Grade C;\n10. Researchers believe that subjects with any other factors that are not suitable for participating in this trial.","ALL","18 Years","80 Years",{"count":118,"type":119},160,"ESTIMATED","INTERVENTIONAL",[122],"PHASE4","This was a multicenter, randomized, open label, non inferiority clinical study. It consisted of a 24-week treatment period (0-24 weeks) and a 24-week extension period (25-48 weeks). About 160 patients which had received Recombinant human erythropoietin (rHuEPO) or Hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) treatment were randomized in a 1:1 ratio to receive Pegmolesatide with different administration regimens.",[125],"Renal Anemia in Non-dialysis Chronic Kidney Disease",[127],"Anemia","NOT_YET_RECRUITING","2025-04-23",{"date":131,"type":132},"2025-04-27","ACTUAL",{"date":134,"type":119},"2025-05",{"date":136,"type":119},"2026-11",{"name":5,"class":6}]